(ALGN) Align Technology - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0162551016

Clear Aligners, Intraoral Scanners, CAD/CAM Software, Whitening System

Stock: Health Care Supplies
Age 25y
MCap 12,431m
Avg Vol 849K (142M USD)
Beta 1.249
Volatility 41.81%

EPS (Earnings per Share)

EPS (Earnings per Share) of ALGN over the last years for every Quarter: "2020-12": 2.61, "2021-03": 2.49, "2021-06": 3.04, "2021-09": 2.87, "2021-12": 2.83, "2022-03": 2.13, "2022-06": 2, "2022-09": 1.36, "2022-12": 1.73, "2023-03": 1.82, "2023-06": 2.22, "2023-09": 2.14, "2023-12": 2.42, "2024-03": 2.14, "2024-06": 2.41, "2024-09": 2.35, "2024-12": 2.44, "2025-03": 2.13, "2025-06": 2.49, "2025-09": 2.61, "2025-12": 0,
EPS CAGR: -47.18%
EPS Trend: -16.6%
Last SUE: -4.00
Qual. Beats: 0

Revenue

Revenue of ALGN over the last years for every Quarter: 2020-12: 834.52, 2021-03: 894.771, 2021-06: 1010.808, 2021-09: 1015.906, 2021-12: 1031.099, 2022-03: 973.219, 2022-06: 969.553, 2022-09: 890.348, 2022-12: 901.515, 2023-03: 943.147, 2023-06: 1002.173, 2023-09: 960.214, 2023-12: 956.726, 2024-03: 997.431, 2024-06: 1028.49, 2024-09: 977.872, 2024-12: 995.219, 2025-03: 979.262, 2025-06: 1012.449, 2025-09: 995.692, 2025-12: null,
Rev. CAGR: -0.93%
Rev. Trend: 35.4%
Last SUE: 0.56
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 41.8%
Value at Risk 5%th 61.0%
Relative Tail Risk -11.29%
Reward TTM
Sharpe Ratio -0.41
Alpha -45.02
CAGR/Max DD -0.22
Character TTM
Hurst Exponent 0.454
Beta 1.249
Beta Downside 0.706
Drawdowns 3y
Max DD 67.59%
Mean DD 36.71%
Median DD 39.27%

Description: ALGN Align Technology January 02, 2026

Align Technology (NASDAQ: ALGN) operates two core segments: the Clear Aligner segment, which markets the Invisalign family of clear aligners, Vivera retainers, and related orthodontic accessories for patients ranging from children to adults; and the Imaging Systems & CAD/CAM Services segment, which sells iTero intra-oral scanners, exocad design software, and a suite of digital workflow tools for restorative and orthodontic practices.

In its most recent fiscal year (2023), Align reported revenue of roughly $5.1 billion, a year-over-year increase of about 20 %, and an adjusted operating margin near 22 %. The company shipped roughly 12 million Invisalign aligners and over 1.2 million iTero scanners, reflecting continued market penetration and strong repeat-purchase rates among dental professionals.

Key growth drivers include the expanding global demand for cosmetic orthodontics (the market is projected to grow at a CAGR of ~7 % through 2028), accelerating adoption of digital dentistry platforms that improve treatment efficiency, and macro-level trends such as higher discretionary spending in developed economies and an aging population seeking aesthetic dental solutions.

For a deeper, data-driven look at ALGN’s valuation and scenario analysis, the ValueRay platform provides a concise, research-ready overview.

Piotroski VR‑10 (Strict, 0-10) 8.0

Net Income: 378.4m TTM > 0 and > 6% of Revenue
FCF/TA: 0.09 > 0.02 and ΔFCF/TA 3.23 > 1.0
NWC/Revenue: 14.25% < 20% (prev 13.48%; Δ 0.78% < -1%)
CFO/TA 0.11 > 3% & CFO 656.1m > Net Income 378.4m
Net Debt (-883.3m) to EBITDA (745.3m): -1.19 < 3
Current Ratio: 1.29 > 1.5 & < 3
Outstanding Shares: last quarter (72.4m) vs 12m ago -3.13% < -2%
Gross Margin: 68.41% > 18% (prev 0.70%; Δ 6771 % > 0.5%)
Asset Turnover: 63.22% > 50% (prev 62.21%; Δ 1.00% > 0%)
Interest Coverage Ratio: 365.5 > 6 (EBITDA TTM 745.3m / Interest Expense TTM 1.56m)

Altman Z'' 3.62

A: 0.09 (Total Current Assets 2.53b - Total Current Liabilities 1.97b) / Total Assets 6.23b
B: 0.39 (Retained Earnings 2.42b / Total Assets 6.23b)
C: 0.09 (EBIT TTM 571.7m / Avg Total Assets 6.30b)
D: 1.09 (Book Value of Equity 2.48b / Total Liabilities 2.28b)
Altman-Z'' Score: 3.62 = AA

Beneish M -3.04

DSRI: 0.98 (Receivables 1.14b/1.16b, Revenue 3.98b/3.96b)
GMI: 1.02 (GM 68.41% / 69.98%)
AQI: 1.04 (AQ_t 0.38 / AQ_t-1 0.37)
SGI: 1.01 (Revenue 3.98b / 3.96b)
TATA: -0.04 (NI 378.4m - CFO 656.1m) / TA 6.23b)
Beneish M-Score: -3.04 = AA

ValueRay F-Score (Strict, 0-100) 64.65

1. Piotroski: 8.0pt
2. FCF Yield: 4.91%
3. FCF Margin: 14.23%
4. Debt/Equity: 0.03
5. Debt/Ebitda: -1.19
6. ROIC - WACC: -1.60%
7. RoE: 9.75%
8. Revenue Trend: 35.36%
9. EPS Trend: -16.57%

What is the price of ALGN shares?

As of January 24, 2026, the stock is trading at USD 168.73 with a total of 391,362 shares traded.
Over the past week, the price has changed by -1.61%, over one month by +7.64%, over three months by +24.07% and over the past year by -28.17%.

Is ALGN a buy, sell or hold?

Align Technology has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy ALGN.
  • Strong Buy: 8
  • Buy: 3
  • Hold: 6
  • Sell: 1
  • Strong Sell: 0

What are the forecasts/targets for the ALGN price?

Issuer Target Up/Down from current
Wallstreet Target Price 180.5 7%
Analysts Target Price 180.5 7%
ValueRay Target Price 162.2 -3.9%

ALGN Fundamental Data Overview January 19, 2026

P/E Trailing = 33.2345
P/E Forward = 16.0
P/S = 3.1212
P/B = 3.1092
P/EG = 1.0252
Revenue TTM = 3.98b USD
EBIT TTM = 571.7m USD
EBITDA TTM = 745.3m USD
Long Term Debt = 121.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 34.0m USD (from shortTermDebt, last quarter)
Debt = 121.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -883.3m USD (from netDebt column, last quarter)
Enterprise Value = 11.55b USD (12.43b + Debt 121.3m - CCE 1.00b)
Interest Coverage Ratio = 365.5 (Ebit TTM 571.7m / Interest Expense TTM 1.56m)
EV/FCF = 20.38x (Enterprise Value 11.55b / FCF TTM 566.6m)
FCF Yield = 4.91% (FCF TTM 566.6m / Enterprise Value 11.55b)
FCF Margin = 14.23% (FCF TTM 566.6m / Revenue TTM 3.98b)
Net Margin = 9.50% (Net Income TTM 378.4m / Revenue TTM 3.98b)
Gross Margin = 68.41% ((Revenue TTM 3.98b - Cost of Revenue TTM 1.26b) / Revenue TTM)
Gross Margin QoQ = 64.20% (prev 69.94%)
Tobins Q-Ratio = 1.85 (Enterprise Value 11.55b / Total Assets 6.23b)
Interest Expense / Debt = 1.29% (Interest Expense 1.56m / Debt 121.3m)
Taxrate = 40.09% (38.0m / 94.7m)
NOPAT = 342.5m (EBIT 571.7m * (1 - 40.09%))
Current Ratio = 1.29 (Total Current Assets 2.53b / Total Current Liabilities 1.97b)
Debt / Equity = 0.03 (Debt 121.3m / totalStockholderEquity, last quarter 3.96b)
Debt / EBITDA = -1.19 (Net Debt -883.3m / EBITDA 745.3m)
Debt / FCF = -1.56 (Net Debt -883.3m / FCF TTM 566.6m)
Total Stockholder Equity = 3.88b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.01% (Net Income 378.4m / Total Assets 6.23b)
RoE = 9.75% (Net Income TTM 378.4m / Total Stockholder Equity 3.88b)
RoCE = 14.29% (EBIT 571.7m / Capital Employed (Equity 3.88b + L.T.Debt 121.3m))
RoIC = 8.83% (NOPAT 342.5m / Invested Capital 3.88b)
WACC = 10.43% (E(12.43b)/V(12.55b) * Re(10.52%) + D(121.3m)/V(12.55b) * Rd(1.29%) * (1-Tc(0.40)))
Discount Rate = 10.52% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.26%
[DCF Debug] Terminal Value 72.05% ; FCFF base≈489.2m ; Y1≈558.3m ; Y5≈769.9m
Fair Price DCF = 136.3 (EV 8.90b - Net Debt -883.3m = Equity 9.78b / Shares 71.7m; r=10.43% [WACC]; 5y FCF grow 16.51% → 2.90% )
EPS Correlation: -16.57 | EPS CAGR: -47.18% | SUE: -4.0 | # QB: 0
Revenue Correlation: 35.36 | Revenue CAGR: -0.93% | SUE: 0.56 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.43 | Chg30d=+0.008 | Revisions Net=+3 | Analysts=11
EPS next Year (2026-12-31): EPS=11.00 | Chg30d=+0.043 | Revisions Net=+1 | Growth EPS=+7.9% | Growth Revenue=+3.8%

Additional Sources for ALGN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle